SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine

被引:2
|
作者
Shuaib, Wan Muhammad Azfar Wan [1 ]
Badaruddin, Izzatul Aliaa [1 ]
Mansor, Munirah [2 ]
Salleh, Sharifah Azura [3 ]
Hassan, Mohd Rohaizat [4 ]
Lindong, Steward [2 ]
Samad, Shahril Nizam [2 ]
Othman, Hanita [1 ]
机构
[1] Univ Kebangsaan Malaysia, Hosp Canselor Tuanku Muhriz, Fac Med, Dept Pathol,UKMMC, Kuala Lumpur, Malaysia
[2] Hosp Canselor Tuanku Muhriz, Dept Lab Diagnost Serv JPMD, UKMMC, Kuala Lumpur, Malaysia
[3] Univ Kebangsaan Malaysia, Hosp Canselor Tuanku Muhriz, Fac Med, Dept Med Microbiol & Immunol,UKMMC, Kuala Lumpur, Malaysia
[4] Univ Kebangsaan Malaysia, Hosp Canselor Tuanku Muhriz, Fac Med, Dept Community Hlth, Kuala Lumpur, Malaysia
关键词
SARS-CoV-2; COVID-19; neutralizing antibodies; healthcare workers; BNT162b2; RISK;
D O I
10.1080/21645515.2023.2266931
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Neutralizing antibodies (NTAb) play a significant role in preventing and protecting against SARS-CoV-2 virus infection. Identifying NTAb is undoubtedly imperative in understanding the immunity toward COVID-19 better. However, it is interesting to note that the production of NTAb varies among individuals, especially among healthcare workers (HCWs), as they are exposed to the virus daily. Hence, we would like to investigate factors affecting the production of S-RBD IgG and NTAb among different categories of HCWs, particularly after receiving the third dose of the BNT162b2 mRNA COVID-19 Vaccine. A total of 361 HCWs from our hospital were prospectively enrolled and had their S-RBD IgG and NTAb titers measured. They were studied in relation to the degree of exposure to COVID-19, breakthrough infections, gender, age, race, household income, housing type, household number, and education levels. HCWs with the highest risk of exposure to COVID-19, breakthrough infections, and male gender displayed the highest median titers of both S-RBD IgG and NTAb, and the differences were statistically significant (p < .05). Age, race, household income, housing type, household number, and education levels were revealed to be insignificant. We concluded that the degree of exposure to COVID-19, breakthrough infections, and male gender are significant factors in NTAb production among HCWs.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
    Gobbi, Federico
    Buonfrate, Dora
    Moro, Lucia
    Rodari, Paola
    Piubelli, Chiara
    Caldrer, Sara
    Riccetti, Silvia
    Sinigaglia, Alessandro
    Barzon, Luisa
    VIRUSES-BASEL, 2021, 13 (03):
  • [22] Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection
    Vicenti, Ilaria
    Gatti, Francesca
    Scaggiante, Renzo
    Boccuto, Adele
    Zago, Daniela
    Basso, Monica
    Dragoni, Filippo
    Zazzi, Maurizio
    Parisi, Saverio Giuseppe
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 108 : 176 - 178
  • [23] Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naive recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
    Trougakos, Ioannis P.
    Terpos, Evangelos
    Zirou, Christina
    Sklirou, Aimilia D.
    Apostolakou, Filia
    Gumeni, Sentiljana
    Charitaki, Ioanna
    Papanagnou, Eleni-Dimitra
    Bagratuni, Tina
    Liacos, Christine-Ivy
    Scorilas, Andreas
    Korompoki, Eleni
    Papassotiriou, Ioannis
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    BMC MEDICINE, 2021, 19 (01)
  • [24] SARS-CoV-2 new infections among health-care workers after the first dose of the BNT162b2 mRNA COVID-19 vaccine. A hospital-wide cohort study
    Guijarro, Carlos
    Galan, Isabel
    Martinez-Ponce, Diana
    Perez-Fernandez, Elia
    Goyanes, Maria Jose
    Castilla, Virgilio
    Velasco, Maria
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (11) : 1699.e1 - 1699.e4
  • [25] Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers
    Sansone, Emanuele
    Sala, Emma
    Tiraboschi, Mara
    Albini, Elisa
    Lombardo, Massimo
    Indelicato, Annamaria
    Rosati, Cristina
    Boniotti, Maria Beatrice
    Castelli, Francesco
    De Palma, Giuseppe
    MEDICINA DEL LAVORO, 2021, 112 (03): : 250 - 255
  • [26] SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
    Falsey, Ann R.
    Frenck, Robert W., Jr.
    Walsh, Edward E.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Bailey, Ruth
    Swanson, Kena A.
    Xu, Xia
    Koury, Kenneth
    Kalina, Warren
    Cooper, David
    Zou, Jing
    Xie, Xuping
    Xia, Hongjie
    Tuereci, Ozlem
    Lagkadinou, Eleni
    Tompkins, Kristin R.
    Shi, Pei-Yong
    Jansen, Kathrin U.
    Sahin, Ugur
    Dormitzer, Philip R.
    Gruber, William C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17): : 1627 - 1629
  • [27] Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
    Moreira, Edson D., Jr.
    Kitchin, Nicholas
    Xu, Xia
    Dychter, Samuel S.
    Lockhart, Stephen
    Gurtman, Alejandra
    Perez, John L.
    Zerbini, Cristiano
    Dever, Michael E.
    Jennings, Timothy W.
    Brandon, Donald M.
    Cannon, Kevin D.
    Koren, Michael J.
    Denham, Douglas S.
    Berhe, Mezgebe
    Fitz-Patrick, David
    Hammitt, Laura L.
    Klein, Nicola P.
    Nell, Haylene
    Keep, Georgina
    Wang, Xingbin
    Koury, Kenneth
    Swanson, Kena A.
    Cooper, David
    Lu, Claire
    Tuereci, Oezlem
    Lagkadinou, Eleni
    Tresnan, Dina B.
    Dormitzer, Philip R.
    Sahin, Ugur
    Gruber, William C.
    Jansen, Kathrin U.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (20): : 1910 - 1921
  • [28] Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine REPLY
    Waxman, Jacob G.
    Magen, Ori
    Hernan, Miguel A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02): : 192 - 192
  • [29] Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine
    Furukawa, Koichi
    Tjan, Lidya Handayani
    Kurahashi, Yukiya
    Sutandhio, Silvia
    Nishimura, Mitsuhiro
    Arii, Jun
    Mori, Yasuko
    JAMA NETWORK OPEN, 2022, 5 (05) : E2210780
  • [30] Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
    Shachor-Meyouhas, Yael
    Dabaja-Younis, Halima
    Magid, Avi
    Leiba, Ronit
    Szwarcwort-Cohen, Moran
    Almog, Ronit
    Mekel, Michal
    Weissman, Avi
    Hyams, Gila
    Gepstein, Vardit
    Horowitz, Nethanel A. A.
    Cohen Saban, Hagar
    Tarabeia, Jalal
    Halberthal, Michael
    Hussein, Khetam
    VACCINES, 2023, 11 (02)